Alfonso Iorio

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3991016/publications.pdf

Version: 2024-02-01

399 papers	17,941 citations	23544 58 h-index	18115 120 g-index
417 all docs	417 docs citations	417 times ranked	20407 citing authors

#	Article	IF	Citations
1	Interventions for enhancing medication adherence. The Cochrane Library, 2014, 2014, CD000011.	1.5	1,352
2	Discrimination and Calibration of Clinical Prediction Models. JAMA - Journal of the American Medical Association, 2017, 318, 1377.	3.8	920
3	d-Dimer Testing to Determine the Duration of Anticoagulation Therapy. New England Journal of Medicine, 2006, 355, 1780-1789.	13.9	593
4	Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature, 2014, 511, 184-190.	13.7	574
5	Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis. New England Journal of Medicine, 2001, 345, 165-169.	13.9	567
6	Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ, The, 2015, 350, h870-h870.	3.0	532
7	Enoxaparin plus Compression Stockings Compared with Compression Stockings Alone in the Prevention of Venous Thromboembolism after Elective Neurosurgery. New England Journal of Medicine, 1998, 339, 80-85.	13.9	522
8	Guideline for opioid therapy and chronic noncancer pain. Cmaj, 2017, 189, E659-E666.	0.9	506
9	The GRADE Working Group clarifies the construct of certainty of evidence. Journal of Clinical Epidemiology, 2017, 87, 4-13.	2.4	455
10	Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. Circulation, 2010, 121, 1838-1847.	1.6	383
11	Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). Journal of Thrombosis and Haemostasis, 2012, 10, 1019-1025.	1.9	353
12	Risk of Recurrence After a First Episode of Symptomatic Venous Thromboembolism Provoked by a Transient Risk Factor. Archives of Internal Medicine, 2010, 170, 1710-6.	4.3	300
13	Effectiveness of Computerized Decision Support Systems Linked to Electronic Health Records: A Systematic Review and Meta-Analysis. American Journal of Public Health, 2014, 104, e12-e22.	1.5	258
14	Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. European Journal of Clinical Pharmacology, 2011, 67, 507-519.	0.8	255
15	Rate of inhibitor development in previously untreated hemophilia A patients treated with plasmaâ€derived or recombinant factor VIII concentrates: a systematic review. Journal of Thrombosis and Haemostasis, 2010, 8, 1256-1265.	1.9	242
16	Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males. Annals of Internal Medicine, 2019, 171, 540.	2.0	228
17	Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ: British Medical Journal, 2011, 342, d813-d813.	2.4	218
18	Low-Molecular-Weight and Unfractionated Heparin for Prevention of Venous Thromboembolism in Neurosurgery. Archives of Internal Medicine, 2000, 160, 2327.	4.3	204

#	Article	IF	Citations
19	GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. Journal of Clinical Epidemiology, 2020, 121, 62-70.	2.4	199
20	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	1.9	188
21	Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patientâ€level metaâ€analysis. Journal of Thrombosis and Haemostasis, 2010, 8, 2436-2442.	1.9	181
22	Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of<scp>d</scp>-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2010, 153, 523.	2.0	149
23	Mortality and causes of death in Italian persons with haemophilia, 1990â€“2007. Haemophilia, 2010, 16, 437-446.	1.0	145
24	Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians. Annals of Internal Medicine, 2017, 166, 279.	2.0	145
25	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	1.9	142
26	Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and metaâ€analysis of randomized controlled trials. Journal of Thrombosis and Haemostasis, 2015, 13, 2012-2020.	1.9	141
27	Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale. Drugs and Aging, 2013, 30, 103-112.	1.3	140
28	Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. Journal of Thrombosis and Haemostasis, 2003, 1, 1906-1913.	1.9	139
29	Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal A systematic review and meta-analysis. Thrombosis and Haemostasis, 2016, 116, 879-890.	1.8	139
30	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. Journal of Clinical Epidemiology, 2020, 123, 120-126.	2.4	130
31	GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. Journal of Clinical Epidemiology, 2017, 87, 14-22.	2.4	124
32	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. Internal and Emergency Medicine, 2014, 9, 723-734.	1.0	121
33	Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open, 2016, 6, e010983.	0.8	110
34	Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood, 2009, 114, 779-784.	0.6	108
35	Association between clusters of diseases and polypharmacy in hospitalized elderly patients: Results from the REPOSI study. European Journal of Internal Medicine, 2011, 22, 597-602.	1.0	104
36	Inhibitor development in haemophilia according to concentrate. Thrombosis and Haemostasis, 2015, 113, 968-975.	1.8	103

#	Article	IF	Citations
37	Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. Journal of Thrombosis and Haemostasis, 2010, 8, 2313-2315.	1.9	100
38	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000â€“18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. Lancet Respiratory Medicine,the, 2021, 9, 33-42.	5.2	100
39	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis. Thrombosis and Haemostasis, 2014, 111, 172-179.	1.8	97
40	Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. Haemophilia, 2012, 18, e101-14.	1.0	96
41	The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica, 2008, 93, 722-728.	1.7	95
42	McMaster RAREâ€Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 2018, 16, 1656-1664.	1.9	95
43	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. The Cochrane Library, 2011, , CD003429.	1.5	92
44	Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia, 2008, 14, 444-453.	1.0	88
45	Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. European Journal of Internal Medicine, 2011, 22, 205-210.	1.0	88
46	Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia, 2014, 20, 44-51.	1.0	86
47	Development of a Web-Accessible Population Pharmacokinetic Serviceâ€"Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Research Protocols, 2016, 5, e239.	0.5	86
48	Bone mineral density in haemophilia patients. Thrombosis and Haemostasis, 2010, 103, 596-603.	1.8	84
49	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. European Journal of Internal Medicine, 2014, 25, 617-623.	1.0	75
50	Core outcome set for gene therapy in haemophilia: Results of the core<scp>HEM</scp> multistakeholder project. Haemophilia, 2018, 24, e167-e172.	1.0	74
51	Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. Blood, 2020, 135, 1788-1810.	0.6	73
52	Risk factors for hospital readmission of elderly patients. European Journal of Internal Medicine, 2013, 24, 45-51.	1.0	72
53	Variation of DNA Fragmentation Levels During Density Gradient Sperm Selection for Assisted Reproduction Techniques. Medicine (United States), 2016, 95, e3624.	0.4	68
54	Individual participant data meta-analyses compared with meta-analyses based on aggregate data. The Cochrane Library, 2016, 2016, MR000007.	1.5	67

#	Article	IF	Citations
55	Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and metaâ€analysis. Journal of Thrombosis and Haemostasis, 2017, 15, 1322-1333.	1.9	67
56	Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2016, 11, e0156891.	1.1	67
57	Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophiliaÂA or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 2461-2465.	1.9	65
58	Influenza A Virus Specific T Cell Immunity in Humans during Aging. Virology, 2002, 299, 100-108.	1.1	60
59	Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophilia, 2005, 11, 589-597.	1.0	60
60	How individual participant data meta-analyses have influenced trial design, conduct, and analysis. Journal of Clinical Epidemiology, 2015, 68, 1325-1335.	2.4	60
61	Evaluation of the utility of the <scp>ISTH</scp>â€<scp>BAT</scp> in haemophilia carriers: a multinational study. Haemophilia, 2016, 22, 912-918.	1.0	60
62	Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia, 2017, 23, e170-e179.	1.0	60
63	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data metaâ€analysis. Journal of Thrombosis and Haemostasis, 2020, 18, 1940-1951.	1.9	60
64	Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. Journal of Medical Internet Research, 2022, 24, e30791.	2.1	60
65	Inhibitor development in previously treated hemophilia A patients: a systematic review, metaâ€analysis, and metaâ€regression. Journal of Thrombosis and Haemostasis, 2013, 11, 1655-1662.	1.9	59
66	Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study. American Journal of Hematology, 2011, 86, 914-917.	2.0	57
67	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Journal of Thrombosis and Haemostasis, 2015, 13, 775-781.	1.9	57
68	Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. American Journal of Hematology, 2009, 84, 584-588.	2.0	56
69	Thrombosis in Inherited Fibrinogen Disorders. Transfusion Medicine and Hemotherapy, 2017, 44, 70-76.	0.7	56
70	Drugâ€“drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiology and Drug Safety, 2013, 22, 1054-1060.	0.9	53
71	Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. European Journal of Internal Medicine, 2010, 21, 516-523.	1.0	51
72	Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia, 2012, 18, 39-45.	1.0	51

#	Article	IF	Citations
73	Residual Venous Obstruction, alone and in Combination with D-Dimer, as a Risk Factor for Recurrence after Anticoagulation Withdrawal following a First Idiopathic Deep Vein Thrombosis in the Prolong Study. European Journal of Vascular and Endovascular Surgery, 2010, 39, 356-365.	0.8	50
74	Impact of Persistent Antiphospholipid Antibodies on Risk of Incident Symptomatic Thromboembolism in Children: A Systematic Review and Meta-Analysis. Seminars in Thrombosis and Hemostasis, 2011, 37, 802-809.	1.5	50
75	NHFâ€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 6-16.	1.0	50
76	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	1.0	50
77	The World Federation of Hemophilia Annual Global Survey 1999â€2018. Haemophilia, 2020, 26, 591-600.	1.0	50
78	Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. Thrombosis and Haemostasis, 2015, 113, 958-967.	1.8	49
79	Management of Inherited<scp>v</scp>on Willebrand Disease in Italy: Results from the Retrospective Study on 1234 Patients. Seminars in Thrombosis and Hemostasis, 2011, 37, 511-521.	1.5	48
80	Uncertainties in baseline risk estimates and confidence in treatment effects. BMJ, The, 2012, 345, e7401-e7401.	3.0	48
81	Haemophilia Experiences, Results and Opportunities (<scp>HERO</scp>) Study: Influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia, 2014, 20, e287-95.	1.0	46
82	Emicizumab and thrombosis: The story so far. Journal of Thrombosis and Haemostasis, 2019, 17, 1269-1272.	1.9	46
83	Clotting factor concentrate switching and inhibitor development in hemophilia A. Blood, 2012, 120, 720-727.	0.6	45
84	Systematic reviews experience major limitations in reporting absolute effects. Journal of Clinical Epidemiology, 2016, 72, 16-26.	2.4	45
85	The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1313-1321.	1.5	44
86	A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study. Journal of Medical Internet Research, 2018, 20, e10281.	2.1	44
87	Pharmacokinetics and the transition to extended halfâ€life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2018, 16, 1437-1441.	1.9	43
88	Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Research Protocols, 2016, 5, e232.	0.5	43
89	Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia, 2014, 20, 527-534.	1.0	42
90	The GRADE evidence-to-decision framework: a report of its testing and application in 15 international guideline panels. Implementation Science, 2015, 11, 93.	2.5	42

#	Article	IF	Citations
91	Hemophilia trials in the twentyâ€first century: Defining patient important outcomes. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 184-192.	1.0	42
92	Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with BehÃ§et's disease and deep vein thrombosis. Arthritis and Rheumatism, 2004, 51, 177-183.	6.7	41
93	Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. Thrombosis and Haemostasis, 2008, 99, 52-58.	1.8	41
94	Using pharmacokinetics to individualize hemophilia therapy. Hematology American Society of Hematology Education Program, 2017, 2017, 595-604.	0.9	39
95	IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. Journal of Clinical Investigation, 2015, 125, 3766-3781.	3.9	39
96	Intracranial Haemorrhage in Patients on Antithrombotics: Clinical Presentation and Determinants of Outcome in a Prospective Multicentric Study in Italian Emergency Departments. Cerebrovascular Diseases, 2006, 22, 286-293.	0.8	38
97	In-Hospital Death and Adverse Clinical Events in Elderly Patients According to Disease Clustering: The REPOSI Study. Rejuvenation Research, 2010, 13, 469-477.	0.9	38
98	Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Medical Research Methodology, 2019, 19, 67.	1.4	38
99	Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. BMC Medical Research Methodology, 2020, 20, 113.	1.4	37
100	Evaluation of an automated method for measuring von <scp>W</scp>illebrand factor activity in clinical samples without ristocetin. International Journal of Laboratory Hematology, 2014, 36, 341-351.	0.7	36
101	Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis, 2017, 117, 1023-1030.	1.8	36
102	A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews. Journal of Clinical Epidemiology, 2017, 84, 37-46.	2.4	35
103	Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia, 2018, 24, 60-67.	1.0	35
104	The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. Pilot and Feasibility Studies, 2018, 4, 58.	0.5	34
105	Comparative pharmacokinetics of two extended halfâ€life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?. Journal of Thrombosis and Haemostasis, 2019, 17, 1085-1096.	1.9	34
106	Defining certainty of net benefit: a GRADE concept paper. BMJ Open, 2019, 9, e027445.	0.8	33
107	Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. , 2010, , CD004449.		32
108	Inâ€hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. International Journal of Geriatric Psychiatry, 2011, 26, 930-936.	1.3	32

#	Article	IF	Citations
109	Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: TheÂEuro Heart Survey. American Journal of Medicine, 2014, 127, 979-986.e2.	0.6	32
110	Prolonged Antithrombin Activity of Low-Molecular-Weight Heparins. Circulation, 1995, 92, 2819-2824.	1.6	32
111	The good use of plasma. A critical analysis of five international guidelines. Blood Transfusion, 2008, 6, 18-24.	0.3	32
112	The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia, 2013, 19, 351-354.	1.0	31
113	Central nervous system bleeding in patients with rare bleeding disorders. Haemophilia, 2012, 18, 34-38.	1.0	30
114	Switching to extended halfâ€life products in Canada â€“ preliminary data. Haemophilia, 2017, 23, e365-e367.	1.0	30
115	Haemophilia Experiences, Results and Opportunities (<scp>HERO</scp>) study: treatmentâ€related characteristics of the population. Haemophilia, 2015, 21, e26-38.	1.0	29
116	A critical appraisal of chronic kidney disease mineral and bone disorders clinical practice guidelines using the AGREE II instrument. International Urology and Nephrology, 2017, 49, 273-284.	0.6	29
117	Authors seldom report the most patient-important outcomes andÂabsoluteÂeffect measures in systematic review abstracts. Journal of Clinical Epidemiology, 2017, 81, 3-12.	2.4	29
118	Dermatan sulphate in heparin-induced thrombocytopenia. Lancet, The, 1994, 344, 1295-1296.	6.3	28
119	Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia, 2006, 12, 128-132.	1.0	27
120	Patientsâ€™, physiciansâ€™, and pharmacistsâ€™ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study. Haemophilia, 2009, 15, 473-486.	1.0	27
121	Concentrate-related inhibitor risk: is a difference always real?. Journal of Thrombosis and Haemostasis, 2011, 9, 2176-2179.	1.9	27
122	Adverse Clinical Events and Mortality During Hospitalization and 3 Months After Discharge in Cognitively Impaired Elderly Patients. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2013, 68, 419-425.	1.7	27
123	The demographics, treatment characteristics and quality of life of adult people with haemophilia in China â€“ results from the <scp>HERO</scp> study. Haemophilia, 2017, 23, 89-97.	1.0	27
124	Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. PLoS ONE, 2017, 12, e0171028.	1.1	27
125	Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. Blood Advances, 2020, 4, 4929-4944.	2.5	27
126	The McMaster Optimal Aging Portal: Usability Evaluation of a Unique Evidence-Based Health Information Website. JMIR Human Factors, 2016, 3, e14.	1.0	27

#	Article	IF	Citations
127	Applicability of the AGREE II Instrument in Evaluating the Development Process and Quality of Current National Academy of Clinical Biochemistry Guidelines. Clinical Chemistry, 2012, 58, 1426-1437.	1.5	26
128	A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia, 2015, 21, 731-735.	1.0	26
129	Cardiovascular disease (CVD) in Canadians with haemophilia: Ageâ€Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia, 2015, 21, 736-741.	1.0	26
130	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. Blood Advances, 2020, 4, 2351-2365.	2.5	26
131	Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPSâ€Hemo project. Haemophilia, 2020, 26, 384-400.	1.0	26
132	Small intestinal bacterial overgrowth and warfarin dose requirement variability. Thrombosis Research, 2010, 126, 12-17.	0.8	25
133	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. European Journal of Internal Medicine, 2015, 26, 330-337.	1.0	25
134	Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor <scp>VIII</scp> Fc fusion protein and conventional recombinant factor <scp>VIII</scp> products. Haemophilia, 2017, 23, 408-416.	1.0	25
135	Development and evaluation of a generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 411-426.	0.8	25
136	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	1.9	25
137	Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 197-201.	0.5	24
138	Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 3074-3077.	1.9	24
139	Perioperative Management of Von Willebrand Disease, a Systematic Review and Meta-Analysis. Blood, 2016, 128, 1408-1408.	0.6	24
140	Miconazole Oral Gel Potentiates Warfarin Anticoagulant Activity. Thrombosis and Haemostasis, 2000, 83, 794-795.	1.8	23
141	Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. Internal and Emergency Medicine, 2013, 8, 509-520.	1.0	23
142	Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematology, 2015, 15, 4.	2.6	23
143	Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. Revista Portuguesa De Pneumologia, 2014, 20, 324-335.	0.7	22
144	Pharmacokinetics of plasmaâ€derived vs. recombinant <scp>FVIII</scp> concentrates: a comparative study. Haemophilia, 2015, 21, 204-209.	1.0	22

#	Article	IF	Citations
145	Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. Journal of Clinical Epidemiology, 2018, 99, 14-23.	2.4	22
146	Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. Thrombosis and Haemostasis, 2019, 119, 368-376.	1.8	22
147	Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology, 2019, 98, 2035-2044.	0.8	22
148	Emicizumab stateâ€ofâ€theâ€art update. Haemophilia, 2022, 28, 103-110.	1.0	22
149	Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. The Cochrane Library, 2020, 2020, CD004449.	1.5	21
150	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. Lancet Haematology,the, 2020, 7, e746-e755.	2.2	21
151	Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. BMJ Open, 2015, 5, e009368.	0.8	20
152	Individualizing Factor Replacement Therapy in Severe Hemophilia. Seminars in Thrombosis and Hemostasis, 2015, 41, 864-871.	1.5	20
153	Care models in the management of haemophilia: a systematic review. Haemophilia, 2016, 22, 31-40.	1.0	20
154	Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. Journal of Clinical Epidemiology, 2020, 117, 46-51.	2.4	20
155	Patientâ€relevant health outcomes for hemophilia care: Development of an international standard outcomes set. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12488.	1.0	20
156	Performance of recalibrated ReFacto^{Â®} laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and oneâ€stage assays after infusion of recalibrated ReFacto^{Â®} (Bâ€domain deleted recombinant factor VIII). Haemophilia, 2009, 15, 779-787.	1.0	19
157	Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research. Canadian Journal of Pain, 2018, 2, 191-204.	0.6	19
158	Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference. Journal of Trauma and Acute Care Surgery, 2021, 91, S19-S25.	1.1	19
159	A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. Journal of Clinical Epidemiology, 2022, 141, 161-171.	2.4	19
160	Increased Plasma Levels of Tissue Factor Pathway Inhibitor (TFPI) after n-3 Polyunsaturated Fatty Acids Supplementation in Patients with Chronic Atherosclerotic Disease. Thrombosis and Haemostasis, 1996, 75, 395-400.	1.8	19
161	Withdrawal of warfarin after deep vein thrombosis. Blood Coagulation and Fibrinolysis, 1999, 10, 291-296.	0.5	18
162	Selective outcome reporting: telling and detecting true lies. The state of the science. Internal and Emergency Medicine, 2010, 5, 151-155.	1.0	18

#	Article	IF	Citations
163	Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia, 2015, 21, e156-66.	1.0	18
164	Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open, 2016, 6, e010569.	0.8	18
165	Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thrombosis Research, 2017, 160, 97-104.	0.8	18
166	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	1.0	18
167	Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (AdynovateÂ®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. Clinical Pharmacokinetics, 2020, 59, 245-256.	1.6	18
168	A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. Blood Transfusion, 2019, 17, 391-398.	0.3	18
169	Patient data metaâ€analysis of Postâ€Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with <scp>rAHF</scp>â€PFM. Haemophilia, 2014, 20, 777-783.	1.0	17
170	Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study. International Journal of Qualitative Studies on Health and Well-being, 2015, 10, 28915.	0.6	17
171	Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. Current Heart Failure Reports, 2017, 14, 197-202.	1.3	17
172	Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics, 2017, 9, 47.	2.0	17
173	Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology, 2020, 99, 2689-2698.	0.8	17
174	Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica, 2002, 87, 948-56.	1.7	17
175	Good or best practice statements: proposal for the operationalisation and implementation of GRADE guidance. BMJ Evidence-Based Medicine, 2023, 28, 189-196.	1.7	17
176	Influenza vaccination in patients on long-term anticoagulant therapy. Vaccine, 2006, 24, 6624-6628.	1.7	16
177	Influenza Vaccination and Vitamin K Antagonist Treatment. Archives of Internal Medicine, 2010, 170, 609-16.	4.3	16
178	Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases. Haemophilia, 2016, 22, 41-50.	1.0	16
179	Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thrombosis and Haemostasis, 2017, 117, 589-594.	1.8	16
180	Nonâ€severe haemophilia: Is it benign? â€“ Insights from the PROBE study. Haemophilia, 2021, 27, 17-24.	1.0	16

#	Article	IF	Citations
181	Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. Blood Coagulation and Fibrinolysis, 1997, 8, 216-222.	0.5	15
182	Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thrombosis Research, 2009, 124, e1-e5.	0.8	15
183	Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. The Cochrane Library, 2010, , CD004888.	1.5	15
184	High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. Journal of Hematology and Oncology, 2013, 6, 63.	6.9	15
185	A methodological survey of the analysis, reporting and interpretation of Absolute Risk ReductiOn in systematic revieWs (ARROW): a study protocol. Systematic Reviews, 2013, 2, 113.	2.5	15
186	Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia, 2014, 20, 200-206.	1.0	15
187	Developing a twoâ€sided intervention to facilitate shared decisionâ€making in haemophilia: decision boxes for clinicians and patient decision aids for patients. Haemophilia, 2014, 20, 800-806.	1.0	15
188	Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development. Haemophilia, 2017, 23, 350-352.	1.0	15
189	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	1.0	15
190	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. American Journal of Medicine, 2018, 131, 430-437.	0.6	15
191	Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open, 2018, 8, e021900.	0.8	15
192	Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. International Journal of Laboratory Hematology, 2005, 27, 283-285.	0.2	14
193	Comparison of Disease Clusters in Two Elderly Populations Hospitalized in 2008 and 2010. Gerontology, 2013, 59, 307-315.	1.4	14
194	Inhibitor development in non-severe haemophilia across Europe. Thrombosis and Haemostasis, 2015, 114, 670-675.	1.8	14
195	Testâ€retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia, 2019, 25, 75-83.	1.0	14
196	Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. Blood Advances, 2020, 4, 2557-2566.	2.5	14
197	Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology, 2019, 12, 1-13.	1.0	14
198	Systematic Review of Randomized Controlled Trials of Prophylactic Clotting Factor Concentrate in Hemophilia.. Blood, 2005, 106, 3114-3114.	0.6	14

#	Article	IF	Citations
199	Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. American Journal of Gastroenterology, 2009, 104, 2335-2341.	0.2	13
200	Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. Systematic Reviews, 2014, 3, 137.	2.5	13
201	Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. Implementation Science, 2014, 9, 125.	2.5	13
202	Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation. Haemophilia, 2017, 23, 648-651.	1.0	13
203	World bleeding disorders registry: The pilot study. Haemophilia, 2018, 24, e113-e116.	1.0	13
204	Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 607-614.	1.0	13
205	Pharmacokineticâ€tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 326-333.	1.0	13
206	Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. Blood Transfusion, 2008, 6, 211-9.	0.3	13
207	Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. Blood Transfusion, 2011, 9, 60-9.	0.3	13
208	Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends?. Haemophilia, 2009, 15, 900-903.	1.0	12
209	Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 800-806.	1.0	12
210	Methodology for the development of the <scp>NHF</scp>â€McMaster Guideline on Care Models for Haemophilia Management. Haemophilia, 2016, 22, 17-22.	1.0	12
211	McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals. BMC Research Notes, 2017, 10, 271.	0.6	12
212	Joint Bleeding Tendencies in Adult Patients With Hemophilia: Itâ€™s Not All Pharmacokinetics. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986205.	0.7	12
213	Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 12-14.	1.0	12
214	Terminal halfâ€life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database. Journal of Thrombosis and Haemostasis, 2021, 19, 1896-1906.	1.9	12
215	Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review. JMIR Medical Informatics, 2021, 9, e30401.	1.3	12
216	Pharmacokinetic Optimisation of the Treatment of Deep Vein Thrombosis. Clinical Pharmacokinetics, 1997, 32, 145-172.	1.6	11

#	Article	IF	Citations
217	Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type1 diabetic patients. Thrombosis and Haemostasis, 2007, 98, 635-641.	1.8	11
218	Prevalence and characteristics of antidepressant drug prescriptions in older Italian patients. International Psychogeriatrics, 2012, 24, 606-613.	0.6	11
219	Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. Journal of Clinical Epidemiology, 2013, 66, 415-425.	2.4	11
220	Factor VIII Products and Inhibitors in Severe Hemophilia A. New England Journal of Medicine, 2013, 368, 1456-1457.	13.9	11
221	Patterns of tertiary prophylaxis in <scp>C</scp>anadian adults with severe and moderately severe haemophilia <scp>B</scp>. Haemophilia, 2014, 20, e199-204.	1.0	11
222	Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. Haemophilia, 2015, 21, 828-831.	1.0	11
223	<scp>FVIII</scp> inhibitor development according to concentrate: data from the <scp>EUHASS</scp> registry excluding overlap with other studies. Haemophilia, 2016, 22, e36-8.	1.0	11
224	Minimal dataset for postâ€registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1878-1881.	1.9	11
225	Exploring regional variations in the crossâ€cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. Haemophilia, 2019, 25, 365-372.	1.0	11
226	The association between platelet transfusions and mortality in patients with critical illness. Transfusion, 2019, 59, 1962-1970.	0.8	11
227	Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex. Molecular and Cellular Biochemistry, 1997, 168, 41-49.	1.4	10
228	Mesenteric-portal Vein Thrombosis in a Patient with Hyperhomocysteinemia and Heterozygous for 20210A Prothrombin Allele. Thrombosis and Haemostasis, 2000, 84, 358-359.	1.8	10
229	Safety and Efficacy of Ximelagatran: Meta-Analysis of the Controlled Randomized Trials for the Prophylaxis or Treatment of Venous Thromboembolism. Current Pharmaceutical Design, 2005, 11, 3893-3918.	0.9	10
230	Performance Comparison of Three Assay Methods Used in Fasting and Postmethionine Load Plasma Homocysteine Determinations From Patients With Vascular Disease. American Journal of Clinical Pathology, 2005, 124, 675-681.	0.4	10
231	Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and onâ€demand treatment in Italy. Transfusion Medicine, 2011, 21, 280-284.	0.5	10
232	Management of Patients With Unprovoked Venous Thromboembolism: An Evidence-Based and Practical Approach. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 224-239.	0.4	10
233	Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study. BioMed Research International, 2013, 2013, 1-7.	0.9	10
234	Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. Haemophilia, 2015, 21, 116-123.	1.0	10

#	Article	IF	Citations
235	Large scale studies assessing antiâ€factor <scp>VIII</scp> antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. British Journal of Haematology, 2017, 178, 20-31.	1.2	10
236	Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia, 2017, 23, e1-e7.	1.0	10
237	Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: protocol for a mixed-method systematic review. Systematic Reviews, 2018, 7, 189.	2.5	10
238	Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clinical Pharmacokinetics, 2020, 59, 605-616.	1.6	10
239	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. Blood Advances, 2021, 5, 4721-4726.	2.5	10
240	User Experiences of the McMaster Optimal Aging Portalâ€™s Evidence Summaries and Blog Posts: Usability Study. JMIR Human Factors, 2016, 3, e22.	1.0	10
241	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2005, , CD003429.		9
242	Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, , CD003429.		9
243	Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. Blood, 2015, 125, 3816-3817.	0.6	9
244	Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia, 2017, 23, 255-263.	1.0	9
245	Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. Journal of Medical Economics, 2017, 20, 337-344.	1.0	9
246	Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary. Journal of Clinical Epidemiology, 2018, 95, 28-33.	2.4	9
247	Experimental evidences on the role of silica nanoparticles surface morphology on the loading, release and activity of three proteins. Microporous and Mesoporous Materials, 2019, 287, 220-227.	2.2	9
248	GRADE Concept Paper 1: Validating the â€œF.A.C.Eâ€•instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement. Journal of Clinical Epidemiology, 2021, 131, 133-140.	2.4	9
249	Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. Haemophilia, 2021, 27, 358-365.	1.0	9
250	Factor product utilization and health outcomes in patients with haemophilia A and B on extended halfâ€life concentrates: A Canadian observational study of realâ€world outcomes. Haemophilia, 2021, 27, 751-759.	1.0	9
251	Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis.. Health Psychology, 2020, 39, 430-451.	1.3	9
252	Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study. Haemophilia, 2016, 22, 23-30.	1.0	8

#	Article	IF	Citations
253	Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 427-438.	0.8	8
254	Multicentre pharmacokinetic evaluation of rFVIIIâ€Fc (efmoroctocog alfa) in a real life and comparison with nonâ€extended halfâ€life FVIII concentrates. Haemophilia, 2020, 26, 282-289.	1.0	8
255	Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. American Journal of Preventive Medicine, 2021, 60, e15-e26.	1.6	8
256	Miconazole oral gel potentiates warfarin anticoagulant activity. Thrombosis and Haemostasis, 2000, 83, 794-5.	1.8	8
257	Joint <scp>WFH</scp>â€<scp>ISTH</scp> session: issues in clinical trial design. Haemophilia, 2014, 20, 137-144.	1.0	7
258	What is the role for population pharmacokinetics in hemophilia?. International Journal of Pharmacokinetics, 2017, 2, 125-136.	0.5	7
259	If You Build It, Who Will Come? A Description of User Characteristics and Experiences With the McMaster Optimal Aging Portal. Gerontology and Geriatric Medicine, 2017, 3, 233372141773768.	0.8	7
260	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	1.0	7
261	Clinical application of Web Accessible Population Pharmacokinetic Serviceâ€"Hemophilia (WAPPSâ€Hemo): Patterns of blood sampling and patient characteristics among clinician users. Haemophilia, 2020, 26, 56-63.	1.0	7
262	Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet-rich plasma. Fibrinolysis, 1993, 7, 379-385.	0.5	6
263	Thrombophilia and Cerebral Vein Thrombosis. , 2007, 23, 55-76.		6
264	The association between venous thromboembolism and physical inactivity in everyday life. BMJ: British Medical Journal, 2011, 343, d3865-d3865.	2.4	6
265	Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. The Cochrane Library, 2015, 2015, CD010561.	1.5	6
266	Report on the International Society for Laboratory Hematology Survey on guidelines to support clinical hematology laboratory practice. International Journal of Laboratory Hematology, 2016, 38, 133-138.	0.7	6
267	Recommendations for authors of manuscripts reporting inhibitor cases developed in previously treated patients with hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1668-1672.	1.9	6
268	Interpreting trial sequential analysis. Transfusion, 2016, 56, 2918-2922.	0.8	6
269	Pointâ€ofâ€care ultrasonography in haemophilia care: Training and competency for muscular haematomas. Haemophilia, 2018, 24, 335-337.	1.0	6
270	A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation. JMIR Research Protocols, 2021, 10, e29398.	0.5	6

#	Article	IF	Citations
271	GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studies. Journal of Clinical Epidemiology, 2022, 143, 202-211.	2.4	6
272	Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal. BMJ Evidence-Based Medicine, 2022, 27, 361-369.	1.7	6
273	Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. Journal of Thrombosis and Haemostasis, 2004, 2, 1055-1057.	1.9	5
274	Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B. Blood, 2009, 114, 4907-4908.	0.6	5
275	First analysis of 10â€year trends in national factor concentrates usage in haemophilia: data from CHARMS , the Canadian Hemophilia Assessment and Resource Management System. Haemophilia, 2014, 20, e251-9.	1.0	5
276	Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study. Journal of Blood Medicine, 2016, Volume 7, 239-253.	0.7	5
277	A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. BMC Hematology, 2016, 16, 17.	2.6	5
278	Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals. Diagnostic and Prognostic Research, 2017, 1, 9.	0.8	5
279	Psychological interventions for people with hemophilia. The Cochrane Library, 2020, 3, CD010215.	1.5	5
280	Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. The Cochrane Library, 2021, 2021, CD014201.	1.5	5
281	Predictors of treatment adherence in patients with chronic disease using the Multidimensional Adherence Model: unique considerations for patients with haemophilia. The Journal of Haemophilia Practice, 2020, 7, 92-101.	0.2	5
282	The haemophilia certification system in Canada. Blood Transfusion, 2014, 12 Suppl 3, e531-41.	0.3	5
283	The impact of extended halfâ€life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12601.	1.0	5
284	New methods facilitated the process of prioritizing questions and health outcomes in guideline development. Journal of Clinical Epidemiology, 2022, 143, 91-104.	2.4	5
285	Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. Journal of Thrombosis and Haemostasis, 2022, 20, 1364-1375.	1.9	5
286	Performance Comparison of Three Assay Methods Used in Fasting and Postmethionine Load Plasma Homocysteine Determinations From Patients With Vascular Disease. American Journal of Clinical Pathology, 2005, 124, 675-681.	0.4	5
287	Residual Vein Thrombosis and D-Dimer for Optimizing Duration of Anticoagulation in Idiopathic Deep Vein Thrombosis. Current Pharmaceutical Design, 2010, 16, 3483-3486.	0.9	4
288	Prospettive di utilizzo della Valutazione Economica e della Budget Impact Analysis nelle politiche del farmaco in Italia: i risultati di uno studio Delphi. Pharmacoeconomics Italian Research Articles, 2012, 14, 3-27.	0.2	4

#	Article	IF	Citations
289	Oral contraceptive use is a provoking factor for venous thromboembolism. BMJ: British Medical Journal, 2017, 357, j2073.	2.4	4
290	The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research, 2018, 170, 53-59.	0.8	4
291	Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. Haemophilia, 2020, 26, 966-974.	1.0	4
292	Extended halfâ€life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 349-355.	1.0	4
293	Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. Journal of Clinical Epidemiology, 2021, 138, 115-127.	2.4	4
294	Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method. BMC Geriatrics, 2021, 21, 665.	1.1	4
295	Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian realâ€world, multicenter, retrospective study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12661.	1.0	4
296	An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance. Journal of Clinical Epidemiology, 2022, 147, 83-94.	2.4	4
297	von Willebrand factor propeptide variants lead to impaired storage and ER retention in patientâ€derived endothelial colonyâ€forming cells. Journal of Thrombosis and Haemostasis, 2022, 20, 1599-1609.	1.9	4
298	Plasma Thrombin Neutralization Assay: Pharmacokinetic Applications. Seminars in Thrombosis and Hemostasis, 1994, 20, 266-273.	1.5	3
299	Choice of End-points in Assessing the Efficacy of Post-discharge Prophylaxis for Venous Thromboembolism. Thrombosis and Haemostasis, 1998, 79, 234-234.	1.8	3
300	Psychological interventions for people with hemophilia. The Cochrane Library, 0, , .	1.5	3
301	Ruling out DVT using the Wells rule and a D-dimer test. BMJ, The, 2014, 348, g1637-g1637.	3.0	3
302	Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Thrombosis and Haemostasis, 2015, 114, 56-64.	1.8	3
303	Computer-Aided Systematic Review Screening Comes of Age. Annals of Internal Medicine, 2017, 167, 210.	2.0	3
304	Exploring some intersections between pharmacokinetics, factor <scp>VIII</scp> measurement and human morphometrics â€“ impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment. Haemophilia, 2017, 23, 488-490.	1.0	3
305	Overall prognosis of preschool autism spectrum disorder diagnoses. The Cochrane Library, 0, , .	1.5	3
306	A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. Thrombosis Research, 2019, 184, 31-37.	0.8	3

#	Article	IF	Citations
307	Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia, 2021, 27, 211-220.	1.0	3
308	Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. Haemophilia, 2021, 27, e596-e608.	1.0	3
309	Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 766-771.	2.2	3
310	Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Blood, 2011, 118, 544-544.	0.6	3
311	Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Thrombosis. Blood, 2015, 126, 430-430.	0.6	3
312	Perioperative Management for Congenital Factor XI Deficiency; A Systematic Review. Blood, 2016, 128, 3796-3796.	0.6	3
313	Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. Thrombosis and Haemostasis, 1996, 75, 395-400.	1.8	3
314	Mesenteric-portal vein thrombosis in a patient with hyperhomocysteinemia and heterozygous for 20210A prothrombin allele. Thrombosis and Haemostasis, 2000, 84, 358-9.	1.8	3
315	Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. Thrombosis and Haemostasis, 2007, 98, 635-41.	1.8	3
316	Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. Vaccine, 2022, 40, 2986-2987.	1.7	3
317	A personalized limited sampling approach to better estimate terminal halfâ€life of <scp>FVIII</scp> concentrates. Journal of Thrombosis and Haemostasis, 0, , .	1.9	3
318	Effect of Dermatan Sulphate on Activated Partial Thromboplastin Time Determined with Different Reagents. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1997, 27, 85-90.	0.5	2
319	Serine base exchange enzyme in porcine lyophilised platelets: enzyme properties and modulation by AlF4- and different types of heparin. Molecular and Cellular Biochemistry, 2000, 203, 177-184.	1.4	2
320	Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence. Internal and Emergency Medicine, 2007, 2, 202-206.	1.0	2
321	Analisi di impatto sul budget di WatchmanTM, dispositivo per la prevenzione tromboembolica nei pazienti con fibrillazione atriale. Pharmacoeconomics Italian Research Articles, 2013, 15, 45-63.	0.2	2
322	Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. South African Medical Journal, 2019, 109, 639.	0.2	2
323	A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. Thrombosis Research, 2020, 196, 550-558.	0.8	2
324	Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dyoxigenase-1 and Heme Oxygenase-1. Frontiers in Immunology, 2020, 11, 620.	2.2	2

#	Article	IF	Citations
325	Evaluation of the sexual health in people living with hemophilia. Haemophilia, 2021, 27, 993-1001.	1.0	2
326	Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 251-260.	1.4	2
327	The Effect of Platelet Transfusion on Death in the Intensive Care Unit. Blood, 2016, 128, 3850-3850.	0.6	2
328	Translating Clinical Questions by Physicians Into Searchable Queries: Analytical Survey Study. JMIR Medical Education, 2020, 6, e16777.	1.2	2
329	User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study. JMIR Human Factors, 2022, 9, e30797.	1.0	2
330	Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and A hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935). Thrombosis Research, 1993, 70, S91.	0.8	1
331	Post-discharge deep-vein thrombosis after orthopaedic surgery. Lancet, The, 1996, 348, 1180.	6.3	1
332	Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. Journal of Thrombosis and Haemostasis, 2003, 1, 881-883.	1.9	1
333	Can evidence harm? Certainly not hemophilia treatment and community. Journal of Thrombosis and Haemostasis, 2006, 4, 505-506.	1.9	1
334	Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No. Journal of Thrombosis and Haemostasis, 2006, 4, 2133-2136.	1.9	1
335	Chronic Prostatitis. New England Journal of Medicine, 2007, 356, 423-424.	13.9	1
336	Clinical efficacy and safety of moroctocog alfa. Clinical Investigation, 2011, 1, 305-316.	0.0	1
337	Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. Haemophilia, 2014, 20, 604-606.	1.0	1
338	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. European Journal of Internal Medicine, 2014, 25, 847-852.	1.0	1
339	Factor Consumption for Prophylaxis and Treatment of Bleeding: Recombinant Factor Ix Fc Fusion Protein Compared With Conventional Recombinant Factor Ix. Value in Health, 2015, 18, A660.	0.1	1
340	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. International Journal of Cardiology, 2016, 203, 785-790.	0.8	1
341	The current state of adverse event reporting in hemophilia. Expert Review of Hematology, 2017, 10, 161-168.	1.0	1
342	Comparison of single subject and populationâ€based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. Haemophilia, 2021, 27, 626-633.	1.0	1

#	Article	IF	Citations
343	Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A. Blood, 2019, 134, 3637-3637.	0.6	1
344	Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. Blood, 2014, 124, 2818-2818.	0.6	1
345	Clinical and Biological Determinants of Bleeding Manifestation in Congenital Factor XI Deficiency; A Systematic Review. Blood, 2016, 128, 1407-1407.	0.6	1
346	Recombinant Factor VIIa Concentrate versus Plasma-derived Concentrates for the Treatment of Acute Bleeding Episodes in Persons with Haemophilia and Inhibitors. European Oncology and Haematology, 2011, 07, 140.	0.0	1
347	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	1.0	1
348	Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor VIII: A Multi-Centre Pilot Study. Blood, 2011, 118, 26-26.	0.6	1
349	Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. Blood, 2018, 132, 4813-4813.	0.6	1
350	Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products. Blood, 2019, 134, 2405-2405.	0.6	1
351	Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. BMJ Open, 2020, 10, e040122.	0.8	1
352	Haemophilia at various stages of life: design of new therapeutic strategies through an interactive course--the Kogeniale project. Blood Transfusion, 2013, 11, 272-80.	0.3	1
353	Sexual issues in people with haemophilia: Awareness and strategies for overcoming communication barriers. Haemophilia, 2021, , .	1.0	1
354	Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. Blood, 2020, 136, 21-22.	0.6	1
355	Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders. European Journal of Haematology, 2022, 108, 232-243.	1.1	1
356	Successful treatment of Dieulafoy's disease in a von Willebrand patient. Haematologica, 2002, 87, ECR23.	1.7	1
357	Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. HemaSphere, 2022, 6, e694.	1.2	1
358	Antipyretic analgesics. Side Effects of Drugs Annual, 1994, 18, 90-98.	0.6	0
359	Streptokinase and rt-PA activate platelets by a different way: Implications on the rethrombosis rate after their administration in myocardial infarction. Fibrinolysis, 1994, 8, 74.	0.5	0
360	Selecting references that match constructs: the difficult job of citing the parachute hyperbole. Internal and Emergency Medicine, 2008, 3, 151-154.	1.0	0

#	Article	IF	Citations
361	Iatrogenic causes of an ICH. European Journal of Anaesthesiology, 2008, 25, 8-11.	0.7	0
362	A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. Annals of Internal Medicine, 2010, 153, JC4.	2.0	0
363	More about optimal choices in cardioembolism prevention. European Journal of Internal Medicine, 2011, 22, e19.	1.0	0
364	The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. Annals of Internal Medicine, 2011, 154, JC6.	2.0	0
365	Erratum to â€œSmall intestinal bacterial overgrowth and warfarin dose requirement variabilityâ€• [Thromb. Res. 126 (1) (2010) 12â€“17]. Thrombosis Research, 2013, 132, e167.	0.8	0
366	Clinical validation of a new algorithm for computerized dosing of vitaminÂK antagonist therapy: a retrospective simulation study. Internal and Emergency Medicine, 2013, 8, 55-63.	1.0	0
367	Modeling The Impact of Potential Differences In Real-Wolrd Adherence With Extended-Half-Life Vs. Conventional Factor Viii And Ix on Bleeding. Value in Health, 2015, 18, A660-A661.	0.1	0
368	Comparisons of Factor Consumption for Routine Prophylaxis And Bleeding During Episodic Therapy With Recombinant Factor Viii Fc Fusion Protein and Conventional Recombinant Factor Viii. Value in Health, 2015, 18, A660.	0.1	0
369	VP57 Test-Retest Reliability Analysis Of The Patient Reported Outcomes Burdens And Experiences (PROBE) Study Questionnaire Test-Retest Reliability Analysis Of The PROBE Study Questionnaire. International Journal of Technology Assessment in Health Care, 2017, 33, 174-175.	0.2	0
370	Haemophilia clinical care and research needs: Assessing priorities. Haemophilia, 2018, 24, e270-e273.	1.0	0
371	An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. Journal of Clinical Epidemiology, 2019, 109, 80-89.	2.4	0
372	High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C.. Blood, 2005, 106, 3219-3219.	0.6	0
373	Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature. Blood, 2008, 112, 3029-3029.	0.6	0
374	Review: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer. Annals of Internal Medicine, 2008, 149, JC6.	2.0	0
375	Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. Blood, 2009, 114, 3993-3993.	0.6	0
376	Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature.. Blood, 2009, 114, 3154-3154.	0.6	0
377	Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients.. Blood, 2009, 114, 3494-3494.	0.6	0
378	A Predictive Model for the Development of High-Responding Inhibitor In Children with Severe and Moderate Hemophilia A- Results of a Multicenter Cohort Study. Blood, 2010, 116, 710-710.	0.6	0

#	Article	IF	Citations
379	Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. Blood, 2010, 116, 238-238.	0.6	0
380	Assessment of Recurrence Risk After Unprovoked Venous Thromboembolism. Annals of Internal Medicine, 2011, 154, 644.	2.0	0
381	Ten-Year Canadian National Prospective Data On Utilization of Anti-Hemophilic Concentrates: Indications and Trends. Blood, 2012, 120, 1186-1186.	0.6	0
382	Hemophilia Experiences, Results and Opportunities (HERO) Study: US Respondent Demographics and Impact of Diagnosis On Career and Lifestyle Decisions and Quality of Life. Blood, 2012, 120, 4244-4244.	0.6	0
383	Non-Anticoagulant Actions of Glycosaminoglycans. , 1996, , 101-112.		0
384	A Systematic Review of Definitions and Reporting of Bleeding Outcome Measures in Hemophilia. Blood, 2014, 124, 2821-2821.	0.6	0
385	Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis of the Prodeswil Study. Blood, 2015, 126, 759-759.	0.6	0
386	Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis. Blood, 2015, 126, 1120-1120.	0.6	0
387	Outcomes of Low-Molecular-Weight Heparintreatment for Venous Thromboembolism in Patients with Primary and Metastatic Brain Tumors. Blood, 2015, 126, 428-428.	0.6	0
388	Installing FVIII-Specific Tolerance in Hemophilia Via Engagement of the Aryl Hydrocarbon Receptor By Tryptophan Derivatives. Blood, 2016, 128, 2563-2563.	0.6	0
389	Interim Canadian Data from a Prospective, Observational Study of Routine Clinical Use of a Von Willebrand Factor Concentrate (WilateÂ®). Blood, 2016, 128, 2593-2593.	0.6	0
390	Warfarin Resumption after Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Blood, 2016, 128, 3821-3821.	0.6	0
391	Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform. Blood, 2018, 132, 1191-1191.	0.6	0
392	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood, 2018, 132, 3781-3781.	0.6	0
393	Routine Double Filtration Plasmapheresis Affects Hemostatic Proteins and Prolongs Clotting Tests. Blood, 2019, 134, 1178-1178.	0.6	0
394	External qualification of the Webâ€Accessible Population Pharmacokinetic Serviceâ€“Hemophilia (WAPPSâ€Hemo) models for octocog alfa using real patient data. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12599.	1.0	0
395	Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. Blood, 2021, 138, 4990-4990.	0.6	0
396	Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood, 2021, 138, 347-347.	0.6	0

#	Article	IF	Citations
397	Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments. Blood, 2020, 136, 22-23.	0.6	0
398	Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Damoctocog Alfa Pegol (BAY) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.6	0
399	Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. Blood, 2020, 136, 37-38.	0.6	0